Philosophiae Doctor - PhD / Background: Oropharyngeal candidiasis, caused by the fungus Candida, is the most common
opportunistic infection affecting the quality of life of immunocompromised patients. Fluconazole
is widely used as the first line of treatment for fungal infections. However, the inappropriate and
misguided use of the drug has led to the evolvement of fluconazole-resistant Candida organisms.
This arising resistance resulted in the urgent need for the development of new antimicrobial
drugs. The aim of the present study was to investigate the antifungal action of K21, a novel
antimicrobial quarternary ammonium compound, on fluconazole-resistant Candida species.
| Identifer | oai:union.ndltd.org:netd.ac.za/oai:union.ndltd.org:uwc/oai:etd.uwc.ac.za:11394/7889 |
| Date | January 2019 |
| Creators | John, Cathy Nisha |
| Contributors | Africa, Charlene WJ |
| Publisher | University of Western Cape |
| Source Sets | South African National ETD Portal |
| Language | English |
| Detected Language | English |
| Rights | University of Western Cape |
Page generated in 0.0017 seconds